Acta Medica Okayama 71巻 6号
2017-12 発行

Feasibility Trial of Oral UFT after Platinum-based Adjuvant Chemotherapy in Patients with Resected Non-small Cell Lung Cancer

Sawada, Shigeki Department of Thoracic Surgery, Japanese Red Cross Society Himeji Hospital
Sugimoto, Ryujiro Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
Ueno, Tsuyoshi Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
Yamashita, Motohiro Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
Publication Date
2017-12
Abstract
We evaluated the feasibility of maintenance treatment using UFT (a combination of tegafur and uracil) after adjuvant platinum-based chemotherapy in patients with resected lung cancer. A prospective feasibility trial was conducted. Between 2010 and 2014, UFT was administered for 2 years sequentially after platinum-based adjuvant chemotherapy in 24 patients with resected Stage IIA-IIIA non-small cell lung cancer. The safety of UFT and the rate of treatment completion were then evaluated. The prior platinum-based chemotherapy regimens consisted of cisplatin+vinorelbine in 16 patients, carboplatin+paclitaxel in 5 and carboplatin+S-1 in one. During the subsequent UFT administration, a total of 3 patients required a dose reduction because of Grade 1 blood-stained sputum, Grade 2 numbness, and Grade 2 constipation, in one patient each. Eleven patients underwent the planned 2-year UFT administration, but 12 patients could not because of the recurrence of lung cancer in 5 patients, metachronous malignancy in one, and toxicities in 6. The completion rate for UFT administration was 64.7% (11/17). The most common type of toxicity was gastrointestinal toxicities. All of the toxicities were grade 1 or 2, and no severe toxicities were observed. UFT treatment after platinum-based chemotherapy was revealed to be feasible.
Document Type
Original Article
Keywords
UFT
adjuvant
chemotherapy
lung cancer
resection
Link to PubMed
Thumnail 71_6_513.pdf 1.93 MB